Table 3.
Patterns of care among patients with lung cancer by clinical subgroup
| Clinical Subgroup/Treatment Received* | n (%) |
|---|---|
| L-NSCLC | |
| Guideline-concordant treatment | |
| Surgery only | 57,605 (49.1) |
| Surgery and chemotherapy | 13,359 (11.4) |
| SBRT only | 11,740 (10.0) |
| Surgery, CRT, and chemotherapy | 4,405 (3.8) |
| Surgery and CRT | 1,562 (1.3) |
| Less intensive treatment than recommended | |
| CRT only | 7,129 (6.1) |
| CRT and chemotherapy | 6,953 (5.9) |
| Chemotherapy only | 1,465 (1.2) |
| LA-NSCLC | |
| Guideline-concordant treatment | |
| CRT and chemotherapy | 36,108 (47.6) |
| Surgery, CRT, and chemotherapy | 5,580 (7.4) |
| Surgery and chemotherapy | 3,335 (4.4) |
| Less intensive treatment than recommended | |
| CRT only | 6,577 (8.7) |
| Chemotherapy only | 6,008 (7.9) |
| Surgery only | 2,676 (3.5) |
| A-NSCLC | |
| Guideline-concordant treatment | |
| CRT and chemotherapy | 47,370 (25.9) |
| Chemotherapy only | 35,620 (19.5) |
| CRT, chemotherapy, and other treatment | 2,970 (1.6) |
| Chemotherapy and other treatment | 2,715 (1.5) |
| Less intensive treatment than recommended | |
| CRT only | 29,219 (16.0) |
| LD-SCLC | |
| Guideline-concordant treatment | |
| CRT and chemotherapy | 13,477 (63.5) |
| Surgery, CRT, and chemotherapy | 545 (2.6) |
| Surgery and chemotherapy | 514 (2.4) |
| Less intensive treatment than recommended | |
| Chemotherapy only | 2,917 (13.7) |
| CRT only | 534 (2.5) |
| Surgery only | 340 (1.6) |
| ED-SCLC | |
| Guideline-concordant treatment | |
| CRT and chemotherapy | 15,671 (35.0) |
| Chemotherapy only | 15,658 (35.0) |
| Less intensive treatment than recommended | |
| CRT only | 2,597 (5.8) |
Definition of abbreviations: A-NSCLC = advanced non–small-cell lung cancer (stage IV); CRT = conventionally fractionated radiotherapy, defined as all radiotherapy other than stereotactic body radiation therapy; ED-SCLC = extensive disease small-cell lung cancer (stage IV); L-NSCLC = localized non–small-cell lung cancer (stages I–II); LA-NSCLC = locally advanced non–small-cell lung cancer (stage III); LD-SCLC = limited-disease small-cell lung cancer (stages I–II); SBRT = stereotactic body radiation therapy, defined as thoracic radiotherapy with a dose of ≥45 Gray in ≤5 fractions.
All mutually exclusive combinations of treatment modalities (i.e., all combinations of surgery, SBRT, CRT, chemotherapy, and other treatment) were assessed. However, for each clinical subgroup, only those treatment combinations that were more prevalent than 1% are reported in this table.